Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised ...
By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...
This NMA serves to bridge the gap between trials for both therapies and compare them to one another based on existing data.
Roche has released positive topline one-year findings from a Phase IV trial of Vabysmo (faricimab) to treat diabetic macular ...
Investor's Business Daily on MSN1d
Roche Retains Outlook After Two Out Of Three Big Hitters Top Sales ExpectationsRoche stock jumped Wednesday after the pharma giant reported light third-quarter sales but kept its 2024 outlook.
Jefferies analyst Peter Welford noted that Roche’s pharma group came just slightly ahead of consensus expectations, driven by ...
A study has shown that Roche's diabetic macular oedema (DME) therapy Vabysmo is effective in patients who identify as African ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline one-year results from ...
Swiss pharma giant Roche (ROG: SIX) on Friday released positive top-line one-year results from the open-label, single-arm ...
The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with diabetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback